Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of re-introduction of pemetrexed + platinum with prolonged bevacizumab in advanced non-squamous NSCLC
2012-002647-18Phase 2Completed
- Sponsor
- IFCT
- Start
- Sep 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in non-small cell lung cancer (NSCLC), sponsored by IFCT. Primary endpoint: Feasibility of second-sequence platinum-based chemotherapy. Started Sep 2012; status: completed.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2012-002647-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002647-18.